T-cell Receptors are the defining feature of T-cells

TCR Technology

Unique TCRs are created each time a new T-cell is produced within the body, which allows T-cells to recognise the massive amount of potential HLA-displayed antigens The production of many millions of new T-cells occurs each day within individuals, and their TCRs are intricately selected against the HLA-antigen repertoire of that individual. This makes finding TCRs that are suitable for targeting antigens for an individual a challenging process, which requires many steps of selection, validation and characterisation to ensure safety and efficacy of those TCRs when deployed in a therapeutic context.

Anocca has created a range of proprietary genetic and cellular tools to identify, characterise and engineer TCRs in an industrialised process. This is based on sophisticated automated TCR gene sequencing coupled to a genetic toolbox to rapidly synthesise TCR genes in the laboratory. Screening and characterisation of identified and synthesised TCRs is conducted using different forms of engineered TCR-presenting cells (eTPC) to carefully select therapeutic TCR candidates. Anocca’s unique genetic and cellular tools can also rapidly engineer TCR candidates to optimise their functionality.

Read about the pipelines »

TCRs can be deployed therapeutically via TCR-modified T-cell therapies. This cell therapy product is produced by purifying T-cells from a patient and equipping them with the selected TCRs specific for disease antigens, prior to reinfusion of the modified T-cells. Anocca has its own manufacturing facility approved by the Swedish authorities for the manufacture of cell therapy products.

Read about the manufacturing capabilities »